Screener / SEC EDGAR /CIK 0001711279 /10-K filed Feb 17, 2026, compared with Feb 19, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Biotechnology

Krystal Biotech, Inc. KRYS

We are a fully integrated, global, commercial-stage biotechnology company focused on the discovery, development, manufacturing and commercialization of genetic medicines to treat diseases with high unmet medical needs. 10-K, Item 1

Headquarters
Pittsburgh, PA
CEO
Krish S. Krishnan
Next results
around Jan 11, 2027
Compare with peers Embed

KRYS among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 33.9%, above 84% of 154 peers (their median 10.4%) REVENUE GROWTH 33.9% · above 84% Operating margin: 48.4%, above 99% of 138 peers (their median 9.8%) OPERATING MARGIN 48.4% · above 99% Net margin: 47.9%, above 99% of 153 peers (their median 6.7%) NET MARGIN 47.9% · above 99% FCF margin: 66.0%, above 100% of 144 peers (their median 9.9%) FCF MARGIN 66.0% · above 100% Return on capital: 12.1%, above 72% of 89 peers (their median 9.0%) RETURN ON CAPITAL 12.1% · above 72%
KRYS Peer median Below the median

What changed

13 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 17, 2026 against Feb 19, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

2facts worth reading about the other 9 checks found nothing to note

  • Cash from operations lower than net income
    Cash from operations $200.9M vs net income $204.8M (FY ending Dec 31, 2025)
  • Inventory growing faster than revenue
    Inventory +52.7% ($26.5M to $40.5M) vs revenue +33.9% ($290.5M to $389.1M), +18.7 pts apart
  • Receivables +21.7% ($104.7M to $127.4M) vs revenue +33.9% ($290.5M to $389.1M), -12.3 pts apart
8 more checks with nothing to note
  • Same auditor in both 10-Ks: KPMG LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Evaluation of the sufficiency of audit evidence over the Medicaid rebate accrual
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

13 paragraphs in Risk Factors that were not in the 10-K filed Feb 19, 2025. Quoted as filed.

All 13 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
    In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal information privacy laws, consumer protection laws, and other similar laws. Notably, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
    There remains substantial uncertainty as to how the current U.S. administration will seek to or continue to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over VYJUVEK and our
  3. Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
    European Commission, MHLW, or other foreign regulators may issue new or revised guidelines concerning the development and marketing authorization of gene therapy medicinal products.
  4. Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
    We were granted RMAT designation for B-VEC from the FDA, and we may seek RMAT designation for some of our product candidates. In 2017, the FDA established the RMAT designation as part of its implementation of the 21st Century Cures Act to expedite review of any drug that meets the following criteria: it qualifies as a RMAT, which is…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$0$50.7M$290.5M$389.1M
Net income−$140.0M$10.9M$89.2M$204.8M
Operating cash flow−$100.6M−$88.8M$123.4M$200.9M
Free cash flow−$153.5M−$100.6M$119.2M$188.9M

Revenue, FY2021 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$389.1M ▲ 33.9% in FY2025

FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

4 filings in the last 30 days · SEC EDGAR

All filings

About the company

Krystal Biotech, Inc., Pittsburgh, PA · from the 10-K filed Feb 17, 2026

We are a fully integrated, global, commercial-stage biotechnology company focused on the discovery, development, manufacturing and commercialization of genetic medicines to treat diseases with high unmet medical needs. Using our patented gene therapy technology platform that is based on engineered herpes simplex virus-1 (“HSV-1”), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell’s own machinery then transcribes and translates the transgene to treat the disease.

Headquarters
Pittsburgh, PA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 2, 2026

Email alerts

Sources

The 10-K filed Feb 17, 2026 (open at SEC), compared with the 10-K filed Feb 19, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/KRYS/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.